

Apresentamos nova(s) oportunidade(s) na sua Área de atuação.

Usaid - Development Innovation Ventures (DIV)

Descrição

The United States Agency for International Development (Usaid) is the lead U.S. Government agency that works to end extreme global poverty and enable resilient, democratic societies to realize their potential. Usaid's mission statement highlights two complementary and intrinsically linked goals: ending extreme poverty and promoting the development of resilient, democratic societies that are able to realize their potential.

The <u>Development Innovation Ventures (DIV)</u> supports breakthrough solutions to the world's most intractable development challenges by finding and testing bold ideas that could change millions of lives at a fraction of the usual cost. The DIV model begins with an open grant competition for innovative ideas, pilots and tests them using cutting-edge analytical methods, and scales solutions that demonstrate widespread impact and cost-effectiveness.

DIV provides financing at <u>Three Stages</u> along an innovation's growth path. Applicants can apply at any stage, and those who have received funding at a prior stage must compete to advance to the next stage:

- 1. Stage 1: Proof of Concept/Initial Testing;
- 2. Stage 2: Testing and Positioning for Scale;
- 3. Stage 3: Transitioning Proven Solutions to Scale.

Data Limite

Letters of Interest may be submited at any time.

Elegibilidade

DIV welcomes applications from U.S. and non-US organizations, individuals, non-profit, and for-profit entities, provided their work is in a country where Usaid operates.

Any organization with a solution for a development challenge in any sector or country in which Usaid operates is eligible to apply.

Valor Financiado

<u>Stage 1</u>: funding levels range from US\$25,000.00 to US\$150,000.00 per project; <u>Stage 2</u>: projects range from US\$150,000.00 to US\$1,500,000.00; <u>Stage 3</u>: projects are broken into two phases:

Category A: awards range from US\$1,500,000.00 to US\$6,000,000.00; Category B: awards range from US\$6,000,000.00 to US\$15,000,000.00.



Restrições

There are several types of projects that are not a good fit for DIV's objectives that includes standard development practice, basic scientific research, a planning tool or diagnostic that is unlikely to result in measurable development impacts, innovations that are applicable only in very limited context, or private sector applications to expand businesses in developing countries that are unlikely to lead to significant development impacts.

Forma de Solicitação

All applicants must submit a <u>Expression of Interest (EOI)</u> for review. Selected applicants will later be invited to submit a Full Application.

All applications must be submitted electronically (Word or PDF) to <u>DIVApplications@usaid.gov</u>.

Note: Applicants must read the <u>How to Apply</u> and <u>Apply to DIV</u> items for more information.

Observações

Applicants may inquire about the status of their application by email to <u>DIV@usaid.gov</u>.

Applicants must read the Frequently Asked Question for information about the Fund.

Contatos

All communication and inquiries should be done through <u>DIV@usaid.gov</u>.

Home Page

http://www.usaid.gov/div

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.

Usaid - Partnering to Accelerate Entrepreneurship (Pace) Initiative 2017

Descrição

The United States Agency for International Development (Usaid), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, DFID, and Koica have joined together to launch Saving Lives at Birth: A Grand Challenge for Development, to find the tools and approaches to help the mothers and newborns during their most vulnerable hours.



The Usaid is making a special call for the <u>Partnering to Accelerate Entrepreneurship (Pace)</u> <u>Initiative</u> focused on fostering entrepreneurship and catalyzing private investment into early stage enterprises operating in developing countries. Usaid launched the Pace initiative to identify and advance innovative approaches or models that enable early stage entrepreneurial enterprises to refine and improve their business models in a manner that achieves commercial viability, scale and sustainable growth, and to increase private investment into such enterprises.

Data Limite

Jul 31, 2017.

Elegibilidade

Usaid welcomes applications from many types of organizations including U.S. and non-U.S. private businesses, business and trade associations, foundations, U.S. and non-U.S. Non-Governmental Organizations (NGOs), faith-based organizations, international organizations, U.S. and non-U.S. colleges and universities, civic groups, regional organizations, etc. All applicants must be legally recognized organizational entities under applicable law.

Valor Financiado

Usaid may allocate up to US\$5,000,000.00 to fund a portfolio of three to five partnerships, with funding for individual partnership proposals estimated in the range of US\$1,000,000.00 to US\$2,000,000.00.

Forma de Solicitação

Applicants are required to follow the Concept Paper instructions and submit Concept Papers using the <u>Concept Paper Template</u>. Before submitting a Concept Paper, prospective applicants are strongly encouraged to submit a request to the <u>Pace team using the PACE 3.0 - Information</u> <u>Request Form</u>.

Note: Applicants must read Application Instructions and Review Proces (page 9) in the <u>Related</u> <u>Documents</u> for more information.

Contatos

Questions regarding the substance and terms should be directed to Ken Lee at <u>kenlee@usaid.gov</u>, with copy to <u>gda@usaid.gov</u>.

Home Page

https://www.grants.gov/web/grants/view-opportunity.html?oppId=293461



Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.

NIH - Modeling of Infectious Disease Agent Study Research Projects (R01)

Descrição

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Composed of <u>27 Institutes and Centers</u>, the NIH provides leadership and financial support to researchers in every state and throughout the world.

The purpose of this funding opportunity announcement (FOA) is to support innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases.

This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

Applicants can access the FOA here: <u>R01</u>.

Data Limite

Letter of Intent Due Date: Not Applicable.

Application Due Dates: February 5, June 5 and October 5, by 5:00 PM local time of applicant organization.

Expiration Date: May 8, 2019.

Elegibilidade

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Foreign (non-US) institutions must follow policies described in the <u>NIH Grants Policy Statement</u>, and procedures for foreign institutions described throughout the Application Guide.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and



ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Applicants must have a valid <u>Dun and Bradstreet Universal Numbering System (DUNS)</u> number in order to begin each of the following registrations: <u>Central Contractor Registration</u> (CCR), <u>Grants.gov</u> and <u>eRA Commons</u>.

Valor Financiado

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Forma de Solicitação

Applicants must access the online <u>Assist System</u> or download the application forms.

It is critical that applicants follow the instructions in the <u>SF424 (R&R) Application Guide</u>, including <u>Supplemental Grant Application Instructions</u> except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, applicants must visit <u>Frequently Asked</u> <u>Questions</u> - Application Guide, Electronic Submission of Grant Applications.

Contatos

Application	Submission	Contacts:
Grants.gov	Customer	Support: <u>support@grants.gov</u>
GrantsInfo: GrantsInfo@	<u>nih.gov</u>	
eRA Commons Help Des	sk: <u>Finding Help Online</u>	
Scientific/Research		Contacts:

Scientific/ResearchContacts:VeerasamyRavichandran: veerasamy.Ravichandra@nih.govMisrak Gezmu: mgezmu@niaid.nih.gov

Home Page

https://grants.nih.gov/grants/guide/pa-files/PAR-17-267.html

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.



SNSF - r4d Programme: Third Thematically Open Call 2017

Descrição

The Swiss National Science Foundation (SNSF) supports basic science in all academic disciplines, from history to medicine and the engineering sciences. The SNSF is Switzerland's foremost research funding organisation and finances projects involving 14,000 researchers each year. By awarding public research money based on a competitive system, the SNSF contributes to the high quality of Swiss research.

The <u>r4d Programme: Third Thematically Open Call</u> supports research on global issues in the context of the 2030 Agenda for Sustainable Development. Global issues are understood as issues that have common causes and require common solutions that go beyond national borders. The research questions of the projects should investigate synergies and dilemmas that exist in the implementation of the 2030 Agenda for Sustainable Development and produce transformative knowledge that will suggest development pathways to reduced poverty and increased sustainability.

Data Limite

June 12, 2017, 17:00 (CET).

Elegibilidade

- 1. The thematically open module invites high-quality research that contributes to the solution of global problems in least developed, low- and middle income countries;
- 2. Researchers employed at a Swiss research institution as well as researchers employed at a research institution in African, Asian and Latin American countries that belong to the category of least developed, low income or lower middle income countries (<u>DAC List</u>) are eligible to receive funding.

Valor Financiado

Each funded project has a running time of maximally four years and a total budget of about CHF600,000.00.

Forma de Solicitação

The pre-proposal must fulfil the following criteria for a successful submission:

- 1. The research plan is submitted in English;
- 2. The research plan must not exceed six pages (excluding cover-page and bibliography), including points 1-6;
- 3. A minimum of point 10 font size and 1.5 line spacing must be used;
- 4. Annexed documents are not accepted;



5. The research plan must be submitted using this form through mySNF.

Contatos

Dr. Stephanie Hoppeler: stephanie.hoppeler@snf.ch

Home Page

http://www.snf.ch/en/researchinFocus/newsroom/Pages/news-170221-call-for-proposals-r4d-programme-third-thematically-open-call.aspx

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.

ADDF - Prevention Beyond the Pipeline RFP 2017

Descrição

Founded in 1998, the Alzheimer's Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer's.

Through <u>Prevention Beyond the Pipeline RFP</u>, the ADDF seeks to support prevention drug discovery not covered by most research funders or its current RFPs.

Data Limite

May	19,	2017;
July	31,	2017;
November 17, 2017.		

Elegibilidade

The funding is open to researchers, clinicians, and postdoctoral fellows working in academia and biotechnology companies, based in the U.S. and worldwide.

Valor Financiado

Funding can range from US\$50,000.00-US\$100,000.00 for epidemiological analyses, US\$150,000.00-US\$600,000.00 for preclinical research, and up to US\$1.5 million for clinical trials.



Forma de Solicitação

Letters of intent must be submitted <u>Online</u>.

Contatos

For program-related inquiries - Yuko Hara: <u>yhara@alzdiscovery.org</u>; For application submission inquiries: <u>grants@alzdiscovery.org</u>.

Home Page

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.

ADDF - Accelerating Drug Discovery for Frontotemporal Degeneration RFP 2017

Descrição

Founded in 1998, the Alzheimer's Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer's.

Research investigating the pathologic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. The ADDF and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative drug discovery programs for FTD through the Request for Proposals (RFP).

Priority areas for the <u>Accelerating Drug Discovery for Frontotemporal Degeneration</u> program include:

- 1. Development and testing of novel high throughput screening assays;
- 2. Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies;
- 3. Testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept;
- 4. Development and/or characterization of new model organisms or cellular models to support drug discovery efforts.



Data Limite

Letter of Intent: July 31, 2017.

Elegibilidade

The funding is open to researchers, clinicians, and postdoctoral fellows working in academia and biotechnology companies, based in the U.S. and worldwide.

Valor Financiado

Funding can range from US\$100,000.00-US\$150,000.00 per year.

Forma de Solicitação

Letters of intent must be submitted <u>Online</u>.

Contatos

For program-related inquiries:

Diana Nadine Tatton: <u>ntatton@theaftd.org</u>. Shineman: <u>dshineman@alzdiscovery.org;</u>

For application submission inquiries: grants@alzdiscovery.org.

Home Page

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.

NIH - Grand Opportunity in Medications Development for Substance-Use Disorders (U01)

Descrição

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research.



Composed of <u>27 Institutes and Centers</u>, the NIH provides leadership and financial support to researchers in every state and throughout the world.

The purpose of the Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance-Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term and large cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

Applicants can access the FOA here: U01.

Data Limite

Letter of Intent Due Date: 30 days prior to the application due date.

U01: July 25, 2017; March 27, 2018; July 25, 2018; March 27, 2019; July 25, 2019, 5:00 PM local time of applicant organization.

Expiration Date: July 26, 2019.

Elegibilidade

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Foreign (non-US) institutions must follow policies described in the <u>NIH Grants Policy Statement</u>, and procedures for foreign institutions described throughout the Application Guide.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Applicants must have a valid <u>Dun and Bradstreet Universal Numbering System (DUNS)</u> number in order to begin each of the following registrations: <u>Central Contractor Registration</u> (CCR), <u>Grants.gov</u> and <u>eRA Commons</u>.

Valor Financiado

Application budgets are limited to US\$5 million per year for direct costs. The maximum project period is three years.



Forma de Solicitação

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the <u>Apply for Grant Electronically</u> or following the directions provided at <u>Grants.gov</u>.

It is critical that applicants follow the instructions in the <u>SF424 (R&R) Application Guide</u>, including <u>Supplemental Grant Application Instructions</u> except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, applicants must visit the <u>Frequently</u> <u>Asked Questions</u> - Application Guide, Electronic Submission of Grant Applications.

Contatos

ApplicationSubmissionContacts:Grants.govCustomerSupport: support@grants.govGrantsInfo:GrantsInfo@nih.goveRA Commons Help Desk: Finding Help Online

Scientific/Research Ivan D. Montoya: <u>imontoya@mail.nih.gov</u> Contact:

Home Page

http://grants.nih.gov/grants/guide/pa-files/PAR-16-431.html

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.

NIH - Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01)

Descrição

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Composed of <u>27 Institutes and Centers</u>, the NIH provides leadership and financial support to researchers in every state and throughout the world.



The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.

It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.

Applicants can access the FOA here: <u>R01</u>.

Data Limite

Letter of Intent Due Date: 30 days prior to the application due date.

R01: July 25, 2017; March 27, 2018; July 25, 2018; March 27, 2019; July 25, 2019, 5:00 PM local time of applicant organization.

Expiration Date: July 26, 2019.

Elegibilidade

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Foreign (non-US) institutions must follow policies described in the <u>NIH Grants Policy Statement</u>, and procedures for foreign institutions described throughout the Application Guide.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Applicants must have a valid <u>Dun and Bradstreet Universal Numbering System (DUNS)</u> number in order to begin each of the following registrations: <u>Central Contractor Registration</u> (CCR), <u>Grants.gov</u> and <u>eRA Commons</u>.

Valor Financiado

Application budgets for direct costs may be up to US\$3,000,000.00 per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years.



Forma de Solicitação

Applicants must obtain the SF424 (R&R) application package associated with this funding opportunity using the <u>Apply for Grant Electronically</u> or following the directions provided at <u>Grants.gov</u>.

It is critical that applicants follow the instructions in the <u>SF424 (R&R) Application Guide</u>, including <u>Supplemental Grant Application Instructions</u> except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, applicants must visit the <u>Frequently</u> <u>Asked Questions</u> - Application Guide, Electronic Submission of Grant Applications.

Contatos

ApplicationSubmissionContacts:Grants.govCustomerSupport: support@grants.govGrantsInfo:GrantsInfo@nih.goveRA Commons Help Desk: Finding Help Online

Scientific/Research Ivan D. Montoya: <u>imontoya@mail.nih.gov</u> Contact:

Home Page

http://grants.nih.gov/grants/guide/pa-files/PAR-16-430.html

Fonte

As informações descritas acima foram obtidas na homepage da Financiadora.